Listed

Innate Pharma SA: Form 20-F for the period ended Dec 31, 2021

Filed with the SEC on Apr 4, 2022 and accepted by EDGAR at Apr 4, 2022, 06:19 ET.

Share

Share this page

Story card, 1080 × 1920

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31EUR 24.7mifrs-full:Revenue
Operating income12 months2021-01-01 to 2021-12-31−EUR 47.8mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2021-01-01 to 2021-12-31EUR 0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2021-01-01 to 2021-12-31−EUR 52.8mifrs-full:ProfitLoss
Diluted EPS12 months2021-01-01 to 2021-12-31−EUR 0.66ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2021-01-01 to 2021-12-31−EUR 0.66ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2021-01-01 to 2021-12-31−EUR 58.5mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31EUR 929.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2021-12-31EUR 103.8mifrs-full:CashAndCashEquivalents
Current assetsAt period end2021-12-31EUR 138.3mifrs-full:CurrentAssets
Total assetsAt period end2021-12-31EUR 267.5mifrs-full:Assets
Current liabilitiesAt period end2021-12-31EUR 79.9mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2021-12-31EUR 107.4mifrs-full:Equity
Shares outstandingAt period end2021-12-3179,542,627 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001628280-22-008197. Last ingested by Listed: Oct 27, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.